ClinicalTrials.gg
CompletedNCT06186583Updated Aug 12, 2024

A Mass Balance Study of [14C]ABSK021

A Phase 1 interventional study of Pimicotinib(ABSK021) in Healthy Subjects, sponsored by Abbisko Therapeutics Co, Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-12.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Male
01

Study summary

This study is a single-site, open-label, single-cohort, single-dose study to assess the absorption, metabolism, and excretion profile of [14C] ABSK021 in healthy adult male subjects. The study plans to enroll 6 to 10 healthy male subjects to ensure at least 6 evaluable subjects.

Read the detailed description

Subjects will be screened within 14 days before dose administration (D-14 to D-3), and will be admitted to the trial ward two days before dose administration (D-2).

On Day 1, subjects will receive a single oral dose of approximately 50 mg ABSK021 containing approximately 100 μCi of [14C] ABSK021 in the fasted state.

All excreted urine and feces samples and blood samples at specified time points during 0-504 hours after dosing will be collected. Random feces within 48 hours prior to dosing and random urine within 24 hours prior to dosing will be collected as blank samples (if there are multiple blank samples, the most recent blank sample before dosing will be selected for analysis).

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Abbisko Therapeutics Co, Ltd is the lead sponsor of 38 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who fully understand the content, procedures and possible adverse reactions before the study, and voluntarily sign the form, and can complete the study in accordance with the requirements in the protocol;
  2. Healthy male subjects aged 18 to 45 years (including 18 and 45 years) at screening;
  3. Weight ≥ 50 kg, (BMI) between 19 and 28 (including 19 and 28), BMI = weight (kg)/height (m) 2;
  4. Subjects must have regular defecation in the past three months;
  5. Male subjects of must agree to use effective methods during the study and within 12 months after administration of study drug . Male subjects must agree to not donate sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Abnormal and complete physical examination, vital signs, digital rectal examination, laboratory tests (hematology, blood biochemistry, urinalysis, coagulation function, stool routine + occult blood, thyroid function, etc.), 12-lead , chest X-ray (anteroposterior position), abdominal B ultrasound (hepatobiliary, pancreas, spleen and kidney);
  2. Abnormal and clinically significant ophthalmic examination (slit lamp, intraocular pressure and fundus photography);
  3. Tested positive for any one of the following: serum surface antigen (HBsAg), hepatitis B e antigen (HBeAg), virus (HCV) antibody, (HIV) antigen/antibody, treponema pallidum antibody (Syphilis) screening;
  4. The baseline of heart rate , QTcF interval prolongs > 450ms; family history of long QT syndrome (Note: QTc interval is corrected by Fridericia formula);
  5. (CrCL) ≤ 60 mL/min, calculated using the Cockcroft-Gault formula ;
  6. Subjects with a history of cardiovascular, respiratory, blood, liver, kidney, gastrointestinal, endocrine or nervous system diseases, for whom the absorption, metabolism or elimination of the drug are significantly affected, or for whom the investigator judges that the disease(s) may pose a risk when taking the test drug, interfere with the interpretation of the data, or affect the ability of the subjects to participate in the study;
  7. Known or persistent mental disorders that may interfere with the subject's participation in the study, as judged by the investigator;
  8. Known history of allergy to any drug or food;
  9. Subjects who have participated in drug trials within 3 months before dosing.
  10. Subjects who have participated in this study or any other study related to ABSK021, and have previously exposed to ABSK021;
  11. Subjects who have used OATP1B1 inhibitors or strong inhibitors or inducers (including grapefruit juice, grapefruit hybrids, pomegranates, carambola, grapefruit, Seville oranges and juice or other processed products) within 14 days prior to dosing;
  12. Subjects with factors that significantly affect drug absorption, distribution, metabolism and excretion, such as inability to take the test drug orally, obvious nausea and vomiting and malabsorption; Subjects with history of gastric or intestinal surgery or resection (appendectomy and hernia repair surgery is allowed);
  13. Subjects who are unwilling to comply with the dietary requirements/restrictions during the study. The specific dietary requirements are: (i) only eat the meals provided by the study sites during hospitalization, (ii) avoid consumption of OATP1B1 inhibitors or strong CYP3A4 inhibitors or inducers during this study;
  14. Subject whose weekly alcohol consumption is greater than 14 units (1 unit of alcohol is equivalent to approximately 360 mL beer, 45 mL of spirits with 40% alcohol or 150 mL wine) within 3 months before dosing, or whose alcohol breath test result is ≥ 20 mg/dl;
  15. Subjects who smoke more than 5 cigarettes per day (or an equivalent amount of tobacco or nicotine) within 3 months prior to dosing;
  16. Subjects with overdose of methylxanthine/caffeine in the past 6 months as judged by the investigator (overdose is defined as more than 6 units of caffeine per day. 1 unit of caffeine is equivalent to 177 mL of coffee, 355 mL of tea, 355 mL of cola or 85 grams of chocolate);
  17. Subjects with a history of bacterial, fungal, parasitic, viral (not including nasopharyngitis), mycobacterial infection within 45 days before dosing;
  18. Known history of drug abuse or tested positive in drug abuse screening;
  19. Subjects who have used or intend to use over-the-counter or prescription drugs, including herbal medicine, within 14 days prior to dosing and during the study;
  20. Subjects who have donated plasma within 30 days before dosing or blood within 3 months before screening, or have experienced blood loss of > 400 mL;
  21. A definite history of hemorrhoids; or perianal disease associated with regular hematochezia or ongoing bleeding, or habitual constipation/diarrhea;
  22. Subjects who have been vaccinated within 2 months prior to dosing, or intend to be vaccinated throughout the study;
  23. Subjects who have participated in the design or implementation of this project and their immediate family members (e.g., employees from Sponsor, CRO or research sites);
  24. Subjects who need to work in a condition with long-term radioactive exposure, or who have experienced significant radioactive exposure (≥ 2 chest/abdominal CTs, or ≥ 3 other types of X-rays) within 1 year prior to the study, or who have participated in studies with radiopharmaceutical labelling;
  25. Subjects with a history of needle sickness or blood sickness, who have difficulty or are intolerant to venipuncture;
  26. Subjects with any other factors that may influence the participation in the study, which may affect the subject's compliance with the protocol, interfere with the interpretation of the study results, or expose the subject to risk, as judged by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [14C]ABSK021 Suspension

    On Day 1, subjects will receive a single oral dose of approximately 50 mg ABSK021 containing approximately 100 μCi of \[14C\] ABSK021 in the fasted state.

    Drug: Pimicotinib(ABSK021)

Interventions

  • DrugPimicotinib(ABSK021)

    A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.

06

What researchers measure

Primary outcomes

  1. Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity (urine and feces)

    To assess the routes and rates of elimination of ABSK021 and its metabolites after single oral administration of \[14C\]ABSK021 in healthy adult male subjects

    Time frame: All excreted urine and feces samples at specified time points during 0-504 hours after dosing will be collected.

  2. Percentage of each metabolite in urine and feces relative to the administered dose (% administered dose), or percentage of metabolites in plasma relative to total exposure AUC (% AUC);

    To determine the metabolism and elimination pathways of ABSK021 after single oral administration of \[14C\] ABSK021 in healthy adult male subjects, and identify major metabolites.All excreted urine and feces samples at specified time points during 0-504 hours after dosing will be collected.

    Time frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol

  3. Identification of major metabolites in plasma, urine, and fecal samples

    To determine the metabolism and elimination pathways of ABSK021 after single oral administration of \[14C\] ABSK021 in healthy adult male subjects, and identify major metabolites.All excreted urine and feces and plasma samples at specified time points during 0-504 hours after dosing will be collected.

    Time frame: Conduct testing within 1 month after all subjects collect plasma, urine, and fecal samplesat all time points required by the protocol

  4. AUC 0-∞

    To evaluate the pharmacokinetics of ABSK021 and its major metabolites in the urine of healthy adult male subjects after a single oral administration \[14C\] of ABSK021.

    Time frame: Conduct testing within 1 month after all subjects collect all samples at all time points required by the protocol

  5. Tmax

    To evaluate the pharmacokinetics of ABSK021 and its major metabolites in the fecal of healthy adult male subjects after a single oral administration \[14C\] of ABSK021

    Time frame: Conduct testing within 1 month after all subjects collect PK samples at all time points required by the protocol

Secondary outcomes

  1. Frequency, type and severity of adverse events/serious adverse events; changes in vital signs, 12-lead ECGs, laboratory tests, etc.

    To assess the safety and tolerability of a single oral dose of approximately 50 mg with approximately 100 μCi \[14C\] ABSK021 in healthy adult male subjects

    Time frame: From signing the ICF until 22 days after the first dosing

07

Study locations

1 site
  • The First Affiliated Hospital of SOOCHOW UNIVERSITY
    Suzhou, Jiangsu 215000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in May 2024, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Jan 2, 2024
StartActual
Dec 13, 2023
Primary completionActual
May 30, 2024
CompletionActual
Jul 30, 2024
Last update
Aug 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06186583
Responsible party
Sponsor
First posted
Jan 2, 2024
Start date
Dec 13, 2023
Primary completion
May 30, 2024
Completion
Jul 30, 2024
Last update
Aug 12, 2024

Study contacts

Liyan Miao, Professor
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion